LGVN News & Events

Reports Q1 revenue $398,000, consensus $323,000. "Earlier this year, we initiated a strategic repositioning of Longeveron designed to maximize shareholder value while maintaining disciplined capital allocation," said Stephen H. Willard, Chief Executive Officer of Longeveron. "We have transitioned toward a more capital-efficient, asset-light operating model, with an increased focus on securing strategic licensing partnerships for our stem cell therapy laromestrocel in four development programs. Longeveron is approaching a series of potentially transformative milestones across these programs that have the potential to redefine the trajectory of our business, with the first catalyst, top line results from our Phase 2b clinical trial in HLHS, anticipated in August of this year."

Longeveron announced that the independent data monitoring committee, or DMC, has completed its final prespecified data review for the ongoing, fully enrolled, Phase 2b clinical trial evaluating laromestrocel as a potential adjunct therapy for hypoplastic left heart syndrome. The DMC based its review on available data for all participating patients enrolled. The DMC performed a risk-benefit assessment, indicated no safety concerns, and approved the study to continue as designed to completion. ELPIS II enrolled 40 pediatric patients at 12 leading pediatric cardiac centers across the country.

Longeveron announced that a constructive Type C meeting with the FDA was held in late March, with the FDA providing their meeting summary in late April, to discuss the ongoing development of laromestrocel, an investigational cellular therapy currently being evaluated in a Phase 2b clinical trial for hypoplastic left heart syndrome. Top-line results from the randomized, controlled Phase 2b ELPIS II clinical trial are anticipated in August 2026. In the Type C meeting, the FDA acknowledged that HLHS is a rare disease associated with significant morbidity and mortality with a high unmet medical need for safe and effective therapies, but also asserted that the primary endpoint of right ventricle ejection fraction in the ELPIS II trial is not an appropriate endpoint to demonstrate efficacy. While Longeveron agreed with the FDA regarding the insufficiency of RVEF as the primary endpoint, and was prepared to discuss other potentially appropriate endpoints sufficient to demonstrate efficacy, the FDA indicated that given the interim analysis mandated and conducted by the National Institute of Health during the trial, a new primary endpoint could not be agreed to while the trial is still ongoing. Without an agreed upon primary endpoint sufficient for efficacy, the FDA no longer refers to the ELPIS II trial as pivotal, as had been specifically discussed in the company's Type C meeting in 2024. Nevertheless, the FDA expressly agreed that it is willing to meet with Longeveron again when the ongoing ELPIS II study is completed to discuss the study results and align on a potential path forward. The FDA further indicated that only the most objective measures, including, all-cause mortality, cardiac transplant-free survival, event of cardiac transplantation, and well-defined major adverse cardiac events, could be informative of efficacy in ELPIS II, and in that regard, the Company is capturing all of these measures in ELPIS II along with some additional key measures to support an efficacy determination. The company intends to submit to the FDA a sponsor statistical analysis plan for ELPIS II with a composite primary endpoint and secondary endpoints for the FDA's review and approval, and remains optimistic that the trial results and other available evidence will be sufficient to support filing a biologics license application following the readout of top-line results of the ELPIS II data.